Table of Contents
JERUSALEM — Teva Pharmaceutical Industries Ltd. has made changes to its executive leadership team.
The company said Monday that Allan Oberman, senior vice president of North America Generic Pharmaceuticals, has been appointed president and chief executive officer of Teva Americas Generics as part of a management succession.
In the new role, Oberman will report to Jeremy Levin, president and CEO of Teva, and have continued responsibility for North America Generics plus overall management of Teva’s Latin American businesses.
Meanwhile, Jill DeSimone has been hired as senior vice president and general manager of Teva Global Women’s Health, a newly created position. In the role she will oversee all aspects of Teva’s Women’s Health franchise. She joins Teva from Bristol-Myers Squibb, where she has held a variety of global leadership positions, mostly as senior vice president of U.S. commercialization excellence.
"These changes are part of our ongoing process to build a premier leadership team and reshape Teva," Levin said in a statement. "Allan brings extensive experience in global generics to the company’s Americas teams. Jill brings a great track record and many years of experience in building franchises in specialty medicine. We look forward to her contributions in leading our Women’s Health business."
Teva also said Monday that as part of the succession, William Marth will step down as president and CEO of Teva Americas effective immediately and retire at the end of 2013. Plans call for Marth to serve as a senior adviser to Levin until his retirement.
"We greatly appreciate the contributions that Bill has made to Teva over the years, most recently leading the Teva businesses in the Americas," Levin commented. "During this time, the company experienced significant growth. We thank him for his tremendous service to the company and look forward to working with him over the next year in his new capacity as a core adviser."
